/
LEGN
$28.88-$0.51 (-1.74%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$5.5B
193M shares
52-week range
$16.24 – $45.30
44% from low
Exchange
NASDAQ
ADRC
Borrow rate
0.25%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-12.90
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $49.1M | $61.8M | $75.0M | $68.8M | $117.0M | $285.1M | $627.2M | $1.03B |
| Cost of revenue | $0 | $0 | $0 | $0 | $65.4M | $144.2M | $234.6M | $408.1M |
| Gross profit | $49.1M | $61.8M | $75.0M | $68.8M | $51.6M | $140.9M | $392.7M | $620.8M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 44.1% | 49.4% | 62.6% | 60.3% |
| R&D | $60.6M | $161.9M | $232.2M | $313.3M | $335.6M | $382.2M | $413.5M | $414.7M |
| Operating income | −$1.5M | −$132.5M | $0 | −$392.3M | −$455.6M | −$439.5M | −$303.2M | −$136.5M |
| EBITDA | $149.0K | −$129.4M | −$298.2M | −$392.4M | −$416.5M | −$477.9M | −$113.2M | −$232.3M |
| Net income | −$2.8M | −$101.6M | −$266.4M | −$403.6M | −$446.3M | −$518.3M | −$177.0M | −$296.8M |
| Net margin | -5.7% | -164.4% | -355.2% | -586.4% | -381.5% | -181.8% | -28.2% | -28.8% |
| EPS (diluted) | -0.03 | -1.01 | -2.57 | -2.74 | -2.81 | -2.94 | -0.97 | -1.60 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.4B | $0.03 | $-0.35–$0.19 | 3 |
| 2027 | $1.8B | $0.82 | $0.19–$1.17 | 4 |
| 2028 | $2.1B | $1.39 | $1.05–$1.72 | 2 |
| 2029 | $2.4B | $1.36 | $1.18–$1.52 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Legend Biotech Corporation American Depositary Shares
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
www.legendbiotech.com- Employees
- 2,900
- IPO / List date
- Jun 5, 2020
Held by traders on TradeandTell
No one on the platform currently holds LEGN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 521,800 | $9.4M |
| Bridgewater Associatesas of 2025-03-31 | 225,449 | $7.6M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded LEGN yet.
